奧替庫單抗
| 單克隆抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | oxLDL |
| 臨床資料 | |
| 其他名稱 | 奧替蘇單抗、BI-204、MLDL1278A |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1314241-10-5 |
| ChemSpider |
|
| UNII | |
奧替庫單抗（INN：Orticumab；開發代號：BI-204、MLDL1278A），或譯奧替蘇單抗，是一種人單克隆抗體，用作抗炎劑並與oxLDL結合。它充當免疫調節劑。[1]該藥物可以用來治療動脈粥樣硬化。[2]該藥物由BioInvent公司研究開發。[3]
參考資料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-01-21]. （原始內容存檔 (PDF)於2016-03-04）.
- ^ Yao Mattisson, Ingrid; Rattik, Sara; Björkbacka, Harry; Ljungcrantz, Irena; Terrinoni, Manuela; Lebens, Michael; Holmgren, Jan; Fredrikson, Gunilla Nordin; Gullstrand, Birgitta; Bengtsson, Anders A.; Nilsson, Jan. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascular Pharmacology. 2021-10-01, 140 [2024-01-21]. ISSN 1537-1891. doi:10.1016/j.vph.2021.106863. （原始內容存檔於2024-07-16）.
- ^ Recruitment of patients completed in phase II study with BI-204. BioInvent. 2012-03-02 [2024-01-21] （英語）.